Chairman, President & CEO of Intra-cellular Therapies Inc (30-Year Financial, Insider Trades) Sharon Mates (insider trades) sold 17,478 shares of ITCI on 01/02/2020 at an average price of $32.45 a share. The total sale was $567,161.
Intra-Cellular Therapies Inc is a biopharmaceutical company. It is engaged in discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders. Intra-Cellular Therapies Inc has a market cap of $1.72 billion; its shares were traded at around $31.17 . GuruFocus has detected 3 severe warning signs with Intra-Cellular Therapies Inc. .
CEO Recent Trades:
- Chairman, President & CEO Sharon Mates sold 17,478 shares of ITCI stock on 01/02/2020 at the average price of $32.45. The price of the stock has decreased by 3.94% since.
CFO Recent Trades:
- SVP of Finance CFO Lawrence J. Hineline sold 7,807 shares of ITCI stock on 01/02/2020 at the average price of $32.43. The price of the stock has decreased by 3.89% since.
- SVP of Finance CFO Lawrence J. Hineline sold 15,032 shares of ITCI stock on 12/23/2019 at the average price of $25.5. The price of the stock has increased by 22.24% since.
Directors and Officers Recent Trades:
- EVP and General Counsel Michael Halstead sold 7,807 shares of ITCI stock on 01/02/2020 at the average price of $32.43. The price of the stock has decreased by 3.89% since.
For the complete insider trading history of ITCI, click here
.
